

SkinBioTherapeutics PLC

14:31 20 Nov 2019

SkinBioTherapeutics teams up with Croda for first commercial deal

SkinBioTherapeutics PLC (LON:SBTX) has inked a commercial agreement for its skincare product with FTSE 100 speciality chemical company Croda International Plc (LON:CRDA).

It secures the AIM-listed life sciences group its first deal and also provides third-party validation of its technology.

Full financial terms were not revealed; however, SkinBioTherapeutics will receive "tiered royalties" on sales of any products that result from the partnership.

The company will be working with Croda unit Sederma, which will design and manufacture "new unique, sustainable, cosmetic ingredients, focusing specifically on the growing skincare actives market".

"This deal offers the potential for SkinBiotix to be incorporated into some of the world's biggest cosmetics brands, which was always the vision that we had for the technology," said Dr Cath O'Neill, SkinBioTherapeutics' chief scientific officer.

The agreement leaves the company free to pursue commercial applications in other sectors.

Sederma managing director Arnaud Fournial said his group had been drawn to the SkinBiotix platform because of its "solid scientific foundation".

"We believe the technology has the potential to become an essential and significant component of cosmetic products within the rapidly emerging skin microbiome market," he explained.

Talking to Proactive Stuart Ashman, SkinBioTherapeutics's chief executive, said that through the deal it is giving Sederma access to its science.

In return, it gets access to the Croda's subsidiary huge base of cosmetic customers and a validated source of supply that it can use in other applications.

"It is our very first commercial deal. It validates the science and gives us a solid industry partner with 12,000 customers and a very credible supply chain."


Skinbiotex uses lysates (extracts) of probiotic bacteria and will be offered as an active ingredient in barrier protection and anti-ageing cosmetics.

Products such as mouthwashes or toothpaste and the other applications such as med-tech, pharma and hospital-acquired infections are not included.

Price: 13.25

Market Cap: £16.97 m

1 Year Share Price Graph



January 2019 July 2019 January 2020

Share Information

Code: SBTX

Listing: AIM

52 week	High	Low
	26	11.5

Sector: Pharma & Biotech

Website: www.skinbiotherapeutics.com

Company Synopsis:

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain at The University of Manchester. The SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin.

action@proactiveinvestors.com

Croda is an excellent partner, Ashman added.

"Going with one of the large brands would have limited us to a single company, this way we get to cover the entire market and every customer of Sederma and Croda now gets exposure to Skinbiotix."

-- adds extra comment --

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).